Found 399 results
Author Keyword Title Type [ Year(Asc)]
F. A. Raja, Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M. K. B., Vergote, I. B., Gonzalez-Martin, A., Alberts, D. S., Plante, M., Torri, V., and Ledermann, J. A., Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data., Ann Oncol, vol. 24, no. 12, pp. 3028-34, 2013.
B. Weber, Largillier, R., Ray-Coquard, I., Yazbek, G., Meunier, J., Alexandre, J., Dauba, J., Spaeth, D., Delva, R., Joly, F., Pujade-Lauraine, E., Copel, L., and France, G. I. N. E. C. O. Group, A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial, Support Care Cancer, vol. 21, pp. 1947-54, 2013.
C. Khoon Lee, Simes, R. J., Brown, C., Gebski, V., Pfisterer, J., Swart, A. Marie, Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I. B., Schauer, C., Pisano, C., Parma, G., Baumann, K. H., Ledermann, J. A., Pujade-Lauraine, E., Bentley, J., Kristensen, G. B., Belau, A., Nankivell, M., Canzler, U., Lord, S. J., Kurzeder, C., and Friedlander, M. Leonard, A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer., Ann Oncol, vol. 24, no. 4, p. 943, 2013.
E. Greimel, Kristensen, G. B., van der Burg, M. E. L., Coronado, P., Rustin, G. J. S., del Rio, A. Sanchez, Reed, N. Simon, Nordal, R. R., Coens, C., and Vergote, I. B., Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy., Gynecol Oncol, vol. 131, no. 2, pp. 437-44, 2013.
D. Stark, Nankivell, M., Pujade-Lauraine, E., Kristensen, G. B., Elit, L., Stockler, M., Hilpert, F., Cervantes, A., Brown, J., Lanceley, A., Velikova, G., Sabate, E., Pfisterer, J., Carey, M. S., Beale, P., Qian, W., Swart, A. Marie, Oza, A. M., and Perren, T. J., Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial., Lancet Oncol, vol. 14, no. 3, p. 243, 2013.
B. You, Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N. Simon, Pignata, S., Varsellona, N., Emons, G., Rehman, K., Steffensen, K. Dahl, Reinthaller, A., Pujade-Lauraine, E., and Oza, A. M., The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)., Gynecol Oncol, vol. 130, no. 2, p. 294, 2013.
J. Alexandre, Brown, C., Coeffic, D., Raban, N., Pfisterer, J., Maenpaa, J. U., Chalchal, H., Fitzharris, B., Volgger, B., Vergote, I. B., Pisano, C., Ferrero, A., and Pujade-Lauraine, E., CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial., Br J Cancer, vol. 106, no. 4, p. 637, 2012.
L. Gladieff, Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P. A., Reinthaller, A., Pujade-Lauraine, E., Reed, N. Simon, Lorusso, D., Siena, S., Helland, H., Elit, L., and Mahner, S., Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial., Ann Oncol, vol. 23, no. 5, pp. 1185-9, 2012.
J. - E. Kurtz, Freyer, G., Joly, F., Gladieff, L., Kaminsky, M. C., Fabbro, M., Floquet, A., Hardy-Bessard, A. C., Raban, N., Ray-Coquard, I., Pujade-Lauraine, E., and France, G. I. N. E. C. O. Group, Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial, Anticancer Res, vol. 32, pp. 1045-9, 2012.
S. Sagae, Aoki, D., Susumu, N., Okamoto, A., Aotani, E., Takeuchi, M., and Mandai, M., [Current movement in global clinical trials–discussion at Gynecologic Cancer Intergroup (GCIG)], Nihon Rinsho, vol. 70 Suppl 4, pp. 59-66, 2012.
A. Casado, Penninckx, B., Reed, N. Simon, van der Burg, M. E. L., Berns, E. M. J. J., Katsaros, D., Ferrero, A., Fernando, M., Jimeno, A., Vermorken, J. B., Pecorelli, S., and Vergote, I. B., EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials. , European Journal Cancer , vol. 10, no. 1, p. 73, 2012.
T. Toita, Kitagawa, R., Hamano, T., Umayahara, K., Hirashima, Y., Aoki, Y., Oguchi, M., Mikami, M., Takizawa, K., and Group, C. Cancer Vul, Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG, Int J Gynecol Cancer, vol. 22, pp. 1420-6, 2012.
U. Wagner, Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I. B., Piccirillo, M. C., Fossati, R., Gebski, V., and Lauraine, E. P., Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients., Br J Cancer, vol. 107, no. 4, p. 591, 2012.
K. Lindemann, Christensen, R. D., Vergote, I. B., Stuart, G. C. E., Izquierdo, M. A., Kærn, J., Havsteen, H., Eisenhauer, E., Ridderheim, M., Lopez, A. B., Hirte, H., Åvall-Lundqvist, E., Vrdoljak, E., Green, J. A., and Kristensen, G. B., First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG., Ann Oncol, vol. 23, no. 10, pp. 2613-9, 2012.
M. Brundage, Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N. Simon, Pignata, S., Ferrero, A., Brown, C., Eisenhauer, E., and Pujade-Lauraine, E., Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial., Ann Oncol, vol. 23, no. 8, p. 2027, 2012.
L. C. Hanker, Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., Ray-Coquard, I., Sehouli, J., Harter, P., du Bois, A., ,, and Group, G. I. N. E. C. O. Study, The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy, Ann Oncol, vol. 23, pp. 2605-12, 2012.
A. Viswanathan, Creutzberg, C. L., Craighead, P., McCormack, M., Toita, T., Narayan, K., Reed, N. Simon, Long, H. J., Kim, H. - J., Marth, C., Lindegaard, J. C., Cerrotta, A., Small, W., and Trimble, E. L., International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG)., Int J Radiat Oncol Biol Phys, vol. 82, no. 1, pp. 250-5, 2012.
E. L. Trimble, Ledermann, J. A., Law, K., Miyata, T., Imamura, C. K., Nam, B. - H., Kim, Y. H., Bang, Y. - J., Michaels, M., Ardron, D., Amano, S., Ando, Y., Tominaga, T., Kurokawa, K., and Takebe, N., International models of investigator-initiated trials: implications for Japan., Ann Oncol, vol. 23, no. 12, pp. 3151-5, 2012.
T. Toita, Kitagawa, R., Hamano, T., Umayahara, K., Hirashima, Y., Aoki, Y., Oguchi, M., Mikami, M., Takizawa, K., and Group, C. Cancer Com, Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule, Gynecol Oncol, vol. 126, pp. 211-6, 2012.
S. Yamaguchi, Nishimura, R., Yaegashi, N., Kiguchi, K., Sugiyama, T., Kita, T., Kubushiro, K., Kokawa, K., Hiura, M., Mizutani, K., Yamamoto, K., and Takizawa, K., Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065)., Oncol Rep, vol. 28, no. 2, pp. 487-93, 2012.
L. M. Randall, Sill, M. W., Burger, R. A., Monk, B. J., Buening, B., and Sorosky, J. I., Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial, Gynecol Oncol, vol. 124, pp. 563-8, 2012.
C. V. Madsen, Steffensen, K. D., Olsen, D. A., Waldstrom, M., Smerdel, M., Adimi, P., Brandslund, I., and Jakobsen, A., Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab, J Ovarian Res, vol. 5, p. 23, 2012.
R. Lindsay, Paul, J., Siddiqui, N. Ahmad, Davis, J., and Gaffney, D. K., Survey on the management of early cervical cancer among members of the GCIG., Int J Gynecol Cancer, vol. 22, no. 9, p. 1623, 2012.
D. ' T. Anna, Signorelli, M., Benedetti-Panici, P., Maggioni, A., Fossati, R., Fruscio, R., Milani, R., Bocciolone, L., Buda, A., Mangioni, C., Scambia, G., Angioli, R., Campagnutta, E., Grassi, R., and Landoni, F., Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial, Br J Cancer, vol. 107, pp. 785-92, 2012.
A. Lortholary, Largillier, R., Weber, B., Gladieff, L., Alexandre, J., Durando, X., Slama, B., Dauba, J., Paraiso, D., Pujade-Lauraine, E., and France, G. I. N. E. C. O. Group, Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Ann Oncol, vol. 23, pp. 346-52, 2012.